Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2018)